Upper gastrointestinal tract bleeding in critically ill pediatric patients

Pharmacotherapy

Volumn 19, Issue 2, 1999, Pages 162-180

  Crill, Catherine M ^a   Hak, Emily B ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Department of Clinical Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ANTACID AGENT; CIMETIDINE; CISAPRIDE; DIAZEPAM; DIGOXIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; ISONIAZID; LANSOPRAZOLE; LIDOCAINE; MIDAZOLAM; NIFEDIPINE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OMEPRAZOLE; PHENYTOIN; PROPAFENONE; PROTON PUMP INHIBITOR; RANITIDINE; STEROID; SUCRALFATE; TETRACYCLINE; THEOPHYLLINE; TOLAZOLINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CRITICAL ILLNESS; DIGESTIVE SYSTEM HEMORRHAGE; DRUG COST; ENTERIC FEEDING; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; IMMUNOPATHOLOGY; LIVER TOXICITY; METABOLIC DISORDER; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; RISK FACTOR; STOMACH ACID SECRETION; STRESS ULCER;

ADOLESCENT; CHILD; CRITICAL ILLNESS; DIGESTIVE SYSTEM; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN;

EID: 0032940775     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.3.162.30914     Document Type: Review

References (249)

1. Lebenthal E, Lee PC, Heitlinger LA. Impact of development of the gastrointestinal tract on infant feeding. J Pediatr 1983;102:1-9.
2. Tyson KR. Normal and abnormal physiology of the alimentary tract in infancy. Am J Surg 1969;117:876-80.
3. Lucas A, Bloom SR, Ansley-Green A. Gastrointestinal peptides and the adaptation to extrauterine nutrition. Can J Physiol Pharmacol 1985;63:527-37.
4. Bryant MG, Buchan AMJ, Gregor M, et al. Development of intestinal regulatory peptides in the human fetus. Gastroenterology 1982;83:47-54.
5. Bisset WM, Watt JB, Rivers RPA, Milla PJ. Ontogeny of fasting small intestinal motor activity in the human infant. Gut 1988;29:483-8.
6. Morriss FH Jr, Moore M, Weisbrodt NW, West MS. Ontogenic development of gastrointestinal motility. IV. Duodenal contractions in preterm infants. Pediatrics 1986;78:1106-13.
7. al Tawil A, Berseth CL. Gestational and postnatal maturation of duodenal motor responses to intragastric feeding. J Pediatr 1996;129:374-81.
8. Lebenthal E, Choi T, Lee PC. The development of pancreatic function in premature infants after milk-based and soy-based formulas. Pediatr Res 1981;15:1240-4.
9. Berseth CL, McCoy HH. Birth asphyxia alters neonatal intestinal motility in term neonates. Pediatrics 1992;90: 669-73.
10. Miller RA. Observations on the gastric acidity during the first month of life. Arch Dis Child 1941;16:22-30.
11. Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969;14:400-14.
12. Euler AR, Byrne WJ, Cousins LM, et al. Increased serum gastrin concentrations and gastric acid hyposecretion in the immediate newborn period Gastroenterology 1977;72:1271-3.
13. Grayzel HG, Elkan B, Moghazeh M, Schneck L, Garza S. Plasma pepsinogen levels in the newborn. Am J Dis Child 1962;103:63-8.
14. Ames MD. Gastric acidity in the first ten days of life of the prematurely born baby. Am J Dis Child 1960;100:122-6.
15. Mason S. Some aspects of gastric function in the newborn. Arch Dis Child 1962;37:387-91.
16. Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Pediatrics 1966;37:1005-7.
17. Harries JT, Fraser AJ. The acidity of the gastric content in premature babies during the first 14 days of life. Biol Neonate 1968;12:186-93.
18. Ebers DW, Smith DI, Gibbs GE. Gastric acidity on the first day of life. Pediatrics 1956;18:800-2.
19. Chhattriwalla Y, Colon AR, Scanlon JW. The use of cimetidine in the newborn. Pediatrics 1980;65:301-2.
20. Aranda JV, Outerbridge EW, Schentag JJ. Pharmacodynamics and kinetics of cimetidine in a premature newborn. Am J Dis Child 1983;137:1207.
21. Hyman PE, Clarke DD, Everett SL, et al. Gastric acid secretory function in preterm infants. J Pediatr 1985;106: 467-71.
22. Treem WR, Davis PM, Hyams JS. Suppression of gastric acid secretion by intravenous administration of famotidine in children. J Pediatr 1991;118:812-16.
23. Euler AR, Byrne WJ, Meis PJ, et al. Basal and pentagastrin-stimulated acid secretion in newborn human infants. Pediatr Res 1979;13:36-7.
24. Hyman PE, Feldman EJ, Ament ME, Byrne WJ, Euler AR. Effect of enteral feeding on the maintenance of gastric acid secretory function. Gastroenterology 1983;84:341-5.
25. DeAngelis GL, Poitevin C, Cezard JP, Vatier J, Foucaud P, Navarro J. Gastric pepsin and acid secretion during total parenteral nutrition and constant-rate enterai nutrition in infancy. J Parenteral Enteral Nutr 1988;12:505-8.
26. Walker V, Taylor WH. Secretion of pepsins and hydrogen ions in the stomach of children undergoing cardiac surgery. Pediatr Res 1980;14:709-14.
27. Lebenthal E, Lee PC. Development of functional response in human exocrine pancreas. Pediatrics 1980;66:556-60.
28. Lebenthal E, Choi TS, Lee PC. The development of pancreatic function in premature infants after milk-based and soy-based formulas. Pediatr Res 1981;15:1240-4.
29. Zoppi G, Andreotti G, Pajno-Ferrara F, Njai DM, Gaburro D. Exocrine pancreas function in premature and full term neonates. Pediatr Res 1972;6:880-6.
30. Mouterde O, Foucaud P, Vatier J, Dupont C, Navarrao J. Duodenogastric reflux in children: measurement of phospholipids and trypsin in gastric content. J Pediatr Gastroenterol Nutr 1990;10:327-34.
31. Sbarbati A, Deganello A, Tamassia G, et al. Surfactant-like material in the antral gastric mucosa of children. J Pediatr Gastroenterol Nutr 1992;15:279-84.
32. Siegel M. Gastric emptying time in premature and compromised infants. J Pediatr Gastroenterol Nutr 1983;2(suppl 1):S136-40.
33. Berseth CL. Gastrointestinal motility in the neonate. Clin Perinatol 1996;23:179-90.
34. Cavell B. Gastric emptying in preterm infants. Acta Paediatr Scand 1979;68:725-30.
35. Blumenthal I, Egbel A, Pildes RS. Effect of posture on the pattern of stomach emptying in the newborn. Pediatrics 1979;63:532-6.
36. Maki M, Ruuska T, Kuusela AL, Karikoski-Leo R, Ikonen RS. High prevalence of asymptomatic esophageal and gastric lesions in preterm infants in intensive care. Crit Care Med 1993;21:1863-7.
37. Kuusela AL, Ruuska T, Karikoski R, et al. A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. Crit Care Med 1997;25:346-51.
38. Reusser P, Gyr K, Scheidegger D, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current frequency and effect of acid-reducing prophylaxis. Crit Care Med 1990;18:270-4.
39. Eddleston JM, Pearson RC, Holland J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Crit Care Med 1994;22:1949-54.
40. Ruiz-Santana S, Ortiz E, Gonzalez B, et al. Stress-induced gastroduodenal lesions and total parenteral nutrition in critically ill patients: frequency, complications, and the value of prophylactic treatment. A prospective, randomized study. Crit Care Med 1991;19:887-91.
41. Solny MN. Antacid by stomach tube in prevention of gastrointestinal bleeding [letter]. N Engl J Med 1979;300:320.
42. Chenoweth AI, Dimick AR. Stress ulcer in infants and children. Ann Surg 1965;161:977-84.
43. Adeyemi SD, Ein SH, Simpson JS. Perforated stress ulcer in infants, a silent threat. Ann Surg 1979;190:706-8.
44. Bell MJ, KeatingJP, Ternberg JL, Bower RJ. Perforated stress ulcers in infants. J Pediatr Surg 1981;16:998-1002.
45. Morden RS, Schullinger JN, Mollitt D, Santulli TV. Operative management of stress ulcers in children. Ann Surg 1982;196:18-20.
46. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding. N Engl J Med 1978;298:1041-5.
47. Lacroix J, Nadeau D, Laberge S, et al. Frequency of upper gastrointestinal bleeding in a pediatric intensive care unit. Crit Care Med 1992;20:35-42.
48. Lacroix J, Infante-Rivard C, Gauthier M, Rousseau E, van Doesburg N. Upper gastrointestinal tract bleeding acquired in a pediatric intensive care unit: prophylaxis trial with cimetidine. J Pediatr 1986;108:1015-18.
49. Cochran EB, Phelps SJ, Tolley EA, Stidham GL. Prevalence of and risk factors for upper gastrointestinal tract bleeding in critically ill pediatric patients. Crit Care Med 1992;20:1519-23.
50. Zhou YP, Zhou ZH, Xue JZ. Burns complicated with gastrointestinal haemorrhage - an analysis of 70 cases. Burns 1993;19:150-2.
51. Zinner MJ, Zuidema GD, Smith PL, et al. The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet 1981;153:214-220.
52. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-81.
53. Sherrill WP. Two case reports of extensive burns in children; both recovered; one with Curling ulcer. Southwest Med 1937;21:135-8.
54. Abramson DJ. Curling's ulcer in childhood: review of the literature and report of five cases. Surgery 1964;55:321-36.
55. Law EJ, Day SB, MacMillan BG. Autopsy finding in the upper gastrointestinal tract of 81 burn patients. Arch Surg 1971;102:412-15.
56. Sevitt S. Duodenal and gastric ulceration after burning. Br J Surg 1967;54:32-41.
57. Bruck HM, Pruitt BA Jr. Curling's ulcer in children: a 12 year review of 63 cases. J Trauma 1972;12:490-6.
58. Watson LC, Abston S. Prevention of upper gastrointestinal hemorrhage in 582 burned children. Am J Surg 1976;132:790-3.
59. Larson GM, Koch S, O'Dorisio TM, et al. Gastric response to severe head injury. Am J Surgery 1984;147:97-103.
60. Idjadi F, Robbins R, Stahl WM, Essiet G. Prospective study of gastric secretion in stressed patients with intracranial injury. J Trauma 1971;11:681-6.
61. Cushing H. Peptic ulcers and the interbrain. Surg Gynecol Obstet 1932;55:1-34.
62. Kamada T, Fusamoto H, Kawano S, et al. Gastrointestinal bleeding after head injury: a clinical study of 433 cases. J Trauma 1977;17:44-7.
63. Ross AJ, Siegel KR, Bell W, et al. Massive gastrointestinal hemorrhage in children with posterior fossa tumors. J Pediatr Surg 1987;22:633-6.
64. Reeder DD, Becker HD, Thompson JC. Effect of intravenously administered calcium on serum gastrin and gastric secretion in man. Surg Gynecol Obstet 1974;138: 847-51.
65. Hyman PE, Everett SL, Harada T. Intravenous amino acids and stimulation of gastric acid secretion in infants. J Pediatr Gastroenterol Nutr 1986;5:62-5.
66. Shimizu T, Yamashiro Y, Yabuta K. Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia. Arch Dis Child 1992;67:470-1.
67. Fadul CE, Lemann W, Thjaler HT, et al. Perforation of the gastrointestinal tract in patients receiving steroids for neurological disease. Neurology 1988;38:348-52.
68. Kelly EJ, Chatfield SL, Brownlee KG, et al. The effect of intravenous ranitidine on the intragastric pH of preterm infants receiving dexamethasone. Arch Dis Child 1993;69:37-9.
69. Ng PC, Brownlee KG, Dear PFT. Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia. Arch Dis Child 1991;66:1164-6.
70. O'Neil EA, Chwals WJ, O'Shea MD, Turner CS. Dexamethasone treatment during ventilator dependency: possible life threatening gastrointestinal complications. Arch Dis Child 1992;67:10-11.
71. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. N Engl J Med 1988;319:964-71.
72. Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. J Infect Dis 1994;169:853-8.
73. Nagaraj HS, Sandhu AS, Cook LN, Buchino JJ, Groff DB. Gastrointestinal perforation after indomethacin therapy in very low birth weight infants. J Pediatr Surg 1981;16:1003-7.
74. Sayles R. Focal intestinal perforation in premature neonates: possible association with indomethacin. J Pediatr Pharm Pract 1997;2:85-9.
75. Dillard RG. Fatal gastrointestinal hemorrhage in a neonate treated with tolazoline. Clin Pediatr 1982;21:761-2.
76. Matsuo M, Aida M, Yamada T, et al. Duodenal perforation with tolazoline therapy [letter]. J Pediatr 1982;100:1005-6.
77. Stevens DC, Schreiner RL, Bull MN, et al. An analysis of tolazoline therapy in the critically-ill neonate. J Pediatr Surg 1980;15:964-70.
78. Wilson RG, George RJ, McCormick WJ, Raine PAM. Duodenal perforation associated with tolazoline. Arch Dis Child 1985;60:878-9.
79. Jones ODH, Shore DF, Rigby ML, et al. The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children. Circulation 1981;64(suppl 2):134-9.
80. Rosenthal M, Miller PW. Ranitidine in the newborn. Arch Dis Child 1988;63:88-9.
81. Watson JW, Brown DM, Lally KP, et al. Complications of extracorporeal membrane oxygenation in neonates. South Med J 1990;83:1262-5.
82. Garland JS, Nelson DB, Rice T, Neu J. Increased risk of gastrointestinal perforations in neonates mechanically ventilated with either face mask or nasal prongs. Pediatrics 1985;76:406-10.
83. Thompson EC, Brown MF, Bowen EC, Smith LM, Gritten DV. Causes of gastrointestinal hemorrhage in neonates and children. South Med J 1996;89:370-4.
84. Goyal A, Treem WR, Hyams JS. Severe upper gastrointestinal bleeding in healthy full term neonates. Am J Gastroenterol 1994;89:613-16.
85. Sherman NJ, Clatworthy HW Jr. Gastrointestinal bleeding in neonates: a study of 94 cases. Surgery 1967;62:614-19.
86. Crill CM, Hak EB, Bugnitz MC. Evaluation of gastric pH and bleeding in neonates receiving ranitidine and antacid during extracorporeal membrane oxygenation [abstr]. Pharmacotherapy 1998;18:436.
87. Ritchie WP Jr. Bile acid-induced acute gastric mucosal damage: a useful experimental model. Scand J Gastroenterol 1981;16(suppl 67):99-101.
88. Salo JA, Kivilaakso E. Role of bile salts and trypsin in the pathogenesis of experimental alkaline esophagitis. Surgery 1983;93:525-32.
89. Kivilaakso E, Fromm D, Silen W. Effect of bile salts and related compounds on esophageal mucosa. Scand J Gastroenterol 1981;16(suppl 67):119-21.
90. Orchard R, Reynolds K, Fox B, et al. Effect of lysolecithin on gastric mucosal structure and potential difference. Gut 1977;18:457-61.
91. Markowitz JF. Duodenogastric reflux: the state of the art. J Pediatr Gastroenterol Nutr 1990;10:287-9.
92. Muller-Lissner SA, Fimmel CJ, Will N, et al. Effect of gastric and transpyloric tubes on gastric emptying and duodenogastric reflux. Gastroenterology 1982;83:1276-9.
93. Slagle TA, Gross SJ. Effect of early low-volume enteral substrate on subsequent feeding tolerance in very low birth weight infants. J Pediatr 1988;113:526-31.
94. Sondheimer JM, Clark DA, Gervaise EP. Continuous gastric pH measurement in young and older healthy preterm infants receiving formula and clear liquid feedings. J Pediatr Gastroenterol Nutr 1985;4:352-5.
95. Macdonald PD, Skeoch CH, Carse H, et al. Randomised trial of continuous nasogastric, bolus nasogastric, and transpyloric feeding in infants of birth weight under 1400 g. Arch Dis Child 1992;67:429-31.
96. Hildreth MA, Herndon DN, Desai MH, Broemeling LD. Current treatment reduced calories required to maintain weight in pediatric patients with burns. J Burn Care Rehabil 1990;11:405-1.
97. Trocki O, Michelini JA, Robbins ST, Eichelberger MR. Evaluation of early enteral feeding in children less than 3 years old with smaller burns (8-25 per cent TBSA). Burns 1995;21:17-23.
98. Solem LD, Strate RG, Fischer RP. Antacid therapy and nutritional supplementation in the prevention of Curling's ulcer. Surg Gynecol Obstet 1979;148:367-70.
99. Eddleston JM, Booker PD, Green GR. Use of ranitidine in children undergoing cardiopulmonary bypass. Crit Care Med 1989;17:26-9.
100. Park GS, Foreman, Bradley JS, Rodarte A, Peterson BM. Stress ulcer prophylaxis in critically ill children [abstr]. Presented at the pediatric critical care colloquium, Waterville Valley, NH, October 3, 1990.
101. Sutphen JL, Dillard VL, Pipan ME. Antacid and formula effects on gastric acidity in infants with gastroesophageal reflux. Pediatrics 1986;78:55-7.
102. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook, 4th ed. Hudson OH: Lexi-Comp, 1997:685.
103. Lopez-Herce J, Dorao P, Elola P, et al. Frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children. A prospective study comparing the efficacy of almagate, ranitidine, and sucralfate. Crit Care Med 1992;20:1082-9.
104. Stile IL, Simon R, Hiatt M, Hegyi T. Pharmacokinetic evaluation of cimetidine in newborn infants. Clin Ther 1985;7:361-4.
105. Martyn JA. Cimetidine and/or antacid for the control of gastric acidity in pediatric burn patients. Crit Care Med 1985;13:1-3.
106. 2-receptor antagonists in children. Drug Intell Clin Pharm 1990;24(11 suppl):S42-6
107. Cochran EB, Storgion SA, Reiter PR, Drwal LD. Effects of continuous vs intermittent ranitidine on gastric pH in critically ill pediatric patients [abstr]. Clin Res 1991;39:833A.
108. Cid JLH, Velasco LA, Codoceo R, et al. Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients. Crit Care Med 1988;16:591-3.
109. James LP, Marotti T, Stowe C, et al. Pharmacokinetics and pharmacodynamics of famotidine in infants [abstr]. J Invest Med 1998;46:7A.
110. Behrens R, Hofbeck M, Singer H, Scharf J, Rupprecht T. Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. Br Heart J 1994;72:186-9.
111. Alliet P, Raes M, Bruneel E, Gillis P. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998;32:352-4.
112. Alliet P, Raes M, Gillis P, Zimmermann A. Optimal dose of omeprazole in infants and children [letter]. J Pediatr 1994;124:332-4.
113. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54.
114. Kato S, Ebina K, Fujii K, Chiba H, Nakagawa H. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996;128:415-21.
115. Kuusela AL. Long term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates. Arch Dis Child Fetal Neonatal Ed 1998;78:F151-3.
116. Dobkin ED, Valcour A, McCloskey CR, et al. Does pH paper accurately reflect gastric pH? Crit Care Med 1990 18;985-8.
117. Caballero GA, Ausman RK, Quebbeman EJ, Schulte WJ, Lin L. Gastric secretion pH measurement: what you see is not what you get! Crit Care Med 1990;18:396-9.
118. McEvoy GK, ed. AHFS 97 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997: 2220-3.
119. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding. N Engl J Med 1978;298:1041-5.
120. Pinson JB, Weart CW. Acid-peptic products. In: Covington TR, Berardi R, Young LL, Kendall SC, Hickey MJ, eds. Handbook of non-prescription drugs. Washington, DC: American Pharmaceutical Association, 1996:204-24.
121. Sedman AB, Klein GL, Merritt RJ, et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med 1985;312:1337-43.
122. Sedman AB, Wilkening GN, Warady BA, Lum GM, Alfrey AC. Encephalopathy in childhood secondary to aluminum toxicity. J Pediatr 1984;105:836-8.
123. Bishop NJ, Morley R, Chir B, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med 1997;336:1557-61.
124. Bozynski MEA, Sedman AB, Naglie RA, Wright EJ. Serial plasma and urinary aluminum levels and tissue loading in preterm twins. J Parenteral Enteral Nutr 1989;13:428-31.
125. Koo WWK. Tissue accumulation of Al in twins [letter]. J Parenteral Enteral Nutr 1990;14:106.
126. American Academy of Pediatrics Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics 1996;97:413-16.
127. Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991;87:148-51.
128. Portuguez-Malavasi A, Aranda J. Antacid bezoar in a newborn [letter]. Pediatrics 1979;63:679-80.
129. Moh P, Gold B. Gastric antacid bezoar in a patient with chronic renal failure [letter]. NY State J Med 1987;87:235-6.
130. Strozik KS, Walele AH, Hoffman H. Bezoar in a preterm baby associated with sucralfate. Clin Pediatr 1996;35:423-4.
131. Hansten PD, Horn JR. Drug interactions analysis and management. Vancouver, WA: Applied Therapeutics, 1997.
132. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcers. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RR, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:901-15.
133. Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982;7:23-41.
134. Maton PN. Drug therapy. Omeprazole. N Engl J Med 1991;324:965-75.
135. Bertz, RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
136. Sandhar BK, Goresky GV, Maltby JR, Shaffer EA. Effect of oral liquids and ranitidine on gastric fluid volume and pH in children undergoing outpatient surgery. Anesthesiology 1989;71:327-30.
137. 2-receptor antagonist with gastrokinetic drugs on gastric fluid pH and volume in children - a comparative study. Int J Clin Pharmacol Ther 1997;35:561-4.
138. Guay J, Santerre L, Gaudreault P, Goulet B, Dupuis C. Effects of oral cimetidine and ranitidine on gastric pH and residual volume in children. Anesthesiology 1989;71:547-9.
139. Goudsouzian NG, Young ET. The efficacy of ranitidine in children. Acta Anaesthesiol Scand 1987;31:387-90.
140. Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR. Effects of famotidine on gastric pH and residual volume in pediatric surgery. Acta Anaesthesiol Scand 1991;35:457-60.
141. Vandeplas Y, Sacre L. Cimetidine influence on gastric emptying time in neonates [letter]. Drug Intell Clin Pharm 1986;20:232-3.
142. Vandeplas Y, Sacre L. The use of cimetidine in newborns. Am J Perinatol 1987;4:131-3.
143. Ziemniak JA, Wynn RJ, Aranda JV, Zarowitz BA, Schentag JJ. The pharmacokinetics and metabolism of cimetidine in neonates. Dev Pharmacol Ther 1984;7:30-8.
144. Chin TWF, MacLeod SM, Fenje P, et al. Pharmacokinetics of cimetidine in critically ill children. Pediatr Pharmacol 1982;2:285-92.
145. Fontana M, Massironi E, Rossi A, et al. Ranitidine pharmacokinetics in newborn infants. Arch Dis Child 1993;68:602-3.
146. James LP, Marshall JD, Heulitt MJ, et al. Pharmacokinetics and pharmacodynamics of famotidine in children. J Clin Pharmacol 1996;36:48-54.
147. Lloyd CW, Martin WJ, Taylor BD. The pharmacokinetics of cimetidine and metabolites in a neonate. Drug Intell Clin Pharm 1985;19:203-5.
148. Lloyd CW, Martin WJ, Taylor BD, Hauser AR. Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. J Pediatr 1985;107: 295-300.
149. Rylance GW, Woods CG, Lamb R. The use of intravenous ranitidine in stressed children [abstr]. Gastroenterology 1988;92:1606.
150. Wiest DB, O'Neal W, Reigart JR, et al. Pharmacokinetics of ranitidine in critically ill infants. Dev Pharmacol Ther 1989;12:7-12.
151. Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients after cardiac surgery. Clin Pharmacokinet 1990;18:77-81.
152. Martyn JA, Greenblatt DJ, Hagen J, Hoaglin DC. Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. Eur J Clin Pharmacol 1989;36:361-7.
153. Wells TG, Heulitt MJ, Taylor BJ, Fasules JW, Kearns GL. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol 1998;38:402-7.
154. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991;21:178-94.
155. Somogyi A, Becker M, Gugler R. Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr 1985;144:72-6.
156. James LP, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in pediatric patients. Clin Pharmacokinet 1996;31:103-10.
157. Santeiro ML, Riggs CD, Weibley RE. Famotidine pharmacodynamics and dosing requirements in critically ill children [abstr]. Pharmacotherapy 1997;17:1103.
158. Harrison AM, Lugo RA, Vernon DD. Gastric pH control in critically ill children receiving intravenous ranitidine. Crit Care Med 1998;26:1433-6.
159. Blumer JL, Rothstein FC, Kaplan BS, et al. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr 1985;107:301-6.
160. Mallet E, Mouterde O, Dubois F, Flipo JL, Moore N. Use of ranitidine in young infants with gastro-oesophageal reflux. Eur J Clin Pharmacol 1989;36:641-2.
161. Morris DL, Markham SJ, Beechey A, et al. Ranitidine - bolus or infusion prophylaxis for stress ulcer. Crit Care Med 1988;16:229-32.
162. Baghaie AA, Mojtahedzadeh M, Levine RL, et al. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. Crit Care Med 1995;23:687-91.
163. Jones LA, Gonzalez ER, Reines HD, Venitz J. Assessment of 24-hour gastric pH measurements in trauma patients receiving intravenous famotidine by intermittent bolus versus continuous infusion administration. Ann Pharmacother 1994;28:841-4.
164. Heiselman DE, Hulisz DT, Fricker R, Bredle DL, Black LD. Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients. Am J Gastroenterology 1995;90:277-9.
165. Osteyee JL, Banner W. Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children. Am J Crit Care 1994;3:267-72.
166. Gedeit RG, Weigle CGM, Havens PL, Werlin SL. Control and variability of gastric pH in critically ill children. Crit Care Med 1993;21:1850-5.
167. Sarna MS, Saili A, Dutta AK, Sharma D. Stress associated gastric bleeding in newborn - role of ranitidine. Indian Pediatr 1991;28:1305-8.
168. Dimand RJ, Burckhart G, Concepcion W, et al. Continuous infusion ranitidine in postoperative pediatric liver transplant patients: effects on intragastric pH, gastrointestinal bleeding and metabolic alkalosis. Am J Therap 1994;1:281-6.
169. Baptista RJ, Palombo JD, Tahan SR, et al. Stability of cimetidine hydrochloride in a total nutrient admixture. Am J Hosp Pharm 1985;42:2208-10.
170. Bullock L, Parks RB, Lampasona V, Mullins RE. Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1985;42:2683-7.
171. Bullock L, Fitzgerald JF, Glick MR, et al. Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. Am J Hosp Pharm 1989;46: 2321-5.
172. Bullock L, Fitzgerald JF, Glick MR. Stability of famotidine 20 and 50 mg/L in total nutrient admixtures. Am J Hosp Pharm 1989;46:2326-9.
173. Allwood MC, Martin H. Factors influencing the stability of ranitidine in TPN mixtures. Clin Nutr 1995;14:171-6.
174. Alvarado-Hughes M, Serrano V, Storm MC. Stability of ranitidine stability in pediatric TPN solutions [abstr]. J Parenteral Enteral Nutr 1994;18:34S.
175. Walker SE, Bayliff CD. Stability of ranitidine hydrochloride in total parenteral nutrient solution. Am J Hosp Pharm 1985;42:590-2.
176. Hatton J, Luer M, Hirsch J, Westrich T, Holstad S. Histamine receptor antagonists and lipid stability in total nutrient admixtures. J Parenteral Enteral Nutr 1994;18: 308-12.
177. Montoro JB, Pou L, Salvador P, Pastor C, Cano SM. Stability of famotidine 20 and 40 mg/L in total nutrient admixtures. Am J Hosp Pharm 1989;46:2329-32.
178. 2-receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol Nutr 1994;19:270-6.
179. Russell WL, Lopez LM. Cimetidine-induced mental status changes: case report and literature review. Am J Hosp Pharm 1980;37:1667-71.
180. Lilly JR, Murr P, Pau C. Cimetidine toxicity [letter]. Pediatrics 1980;4:652.
181. Thompson J, Lilly JR. Cimetidine-induced cerebral toxicity in children [letter]. Lancet 1979;1:725.
182. Bale JF Jr, Roberts C, Book LS. Cimetidine-induced cerebral toxicity in children [letter]. Lancet 1979;1:725-6.
183. Goelzer SL, Coursin DB, Farin-Rusk C. Ranitidine produces minimal hemodynamic depression [reply]. Crit Care Med 1989;17:485.
184. Coursin DB, Farin-Rusk C, Springman SR, Goelzer SL. The hemodynamic effects of intravenous cimetidine versus ranitidine in intensive care unit patients: a double-blind, prospective, cross-over study. Anesthesiology 1988;69:975-8.
185. Lilly JR, Hitch DC, Javitt NB. Cimetidine cholestatic jaundice in children. J Surg Res 1978;24:384-7.
186. Glade G, Saccar CL, Pereira GR. Cimetidine in pregnancy: apparent transient liver impairment in the newborn. Am J Dis Child 1980;134:87-8.
187. Van Thiel DH, Gavaler JS, Smith WI, Paul G. Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med 1979;300:1012-15.
188. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989;321: 269-74.
189. Socha J, Rondio H, Chaba-Celinska D, Rasinski A, Bogoniowska Z. Treatment of hyperchlorhydria in children and teenagers with ranitidine and cimetidine [abstr]. Scand J Gastroenterol 1982;17(suppl 78):195.
190. Bosman JM, Bax NMA, Wit JM. Premature thelarche: a possible adverse effect of cimetidine treatment. Eur J Pediatr 1990;149:534-5.
191. De Giacomo C, Maggiore G, Scotta MS. Ranitidine and loss of colour vision in a child [letter]. Lancet 1984;2:47.
192. Tryba M. Side effects of stress bleeding prophylaxis. Am J Med 1989;86(suppl 6A):85-93.
193. 2-receptor antagonists. J Clin Pharmacol 1995;35:107-16.
194. Kirch W, Halabi A, Linde M, Santos SR, Ohnhaus EE. Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 1989;96:1388-92.
195. Balestrazzi P, Gregori G, Bernasconi S, Giovannelli G. Bradycardia and neurologic disorders associated with ranitidine in a child [letter]. Am J Dis Child 1985;139:442.
196. Nahum E, Reish O, Naor N, Merlob P. Ranitidine-induced bradycardia in a neonate - a first report. Eur J Pediatr 1993;152:933-4.
197. Fontana M, Tornaghi R, Petrillo M, et al. Ranitidine treatment in newborn infants: effects on gastric acidity and serum prolactin levels. J Pediatr Gastroenterol Nutr 1993;16:406-11.
198. Gifford RRM, Tilberg AF. Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987;102:242-7.
199. Hellstrand K, Hermodsson S. Differential effects of histamine receptor antagonists on human natural killer cell activity. Int Arch Allergy Appl Immunol 1987;84:247-55.
200. 2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Therap 1990;4:47-63.
201. 2-receptor antagonists. Aliment Pharmacol Ther 1990;4: 15-27.
202. 2-receptor antagonist. Gut 1988;29:890-3.
203. 2 antagonist efficacy during a 24-hour continuous infusion [abstr]. Gastroenterology 1990;98:A16.
204. Hyman PE, Garvey TQ, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr 1987;110:794-6.
205. Hyman PE, Garvey TQ, Harada T. Effect of ranitidine on gastric acid hypersecretion in an infant with short bowel syndrome. J Pediatr Gastroenterol Nutr 1985;4:316-19.
206. Nwokolo Cu, Smith JTL, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4:29-45.
207. Ostro MJ, Russell JA, Soldin SJ, Mahon WA, Jeejeebhoy KN. Control of gastric pH with cimetidine: boluses versus primed infusions. Gastroenterology 1985;89:532-7.
208. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992.
209. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
210. Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984;9: 493-510.
211. Ted Tse CS, Akinwande KI, Biallowons K. Phenytoin concentration elevation subsequent to ranitidine administration. Ann Pharmacother 1993;27:1448-51.
212. 2-receptor antagonists: an update. Pharmacotherapy 1987;7(6 Pt 2):110S-15.
213. Shinn AF. Unrecognized drug interactions with famotidine and nizatidine [letter]. Arch Intern Med 1991;151:814.
214. Shulman RJ. Cisapride and the attack of the P-450s. J Pediatr Gastroenterol Nutr 1996;23:395-7.
215. Gunasekaran TS, DuBrow I. Cisapride-induced long QT interval: what is the role of ranitidine [letter]? J Pediatr 1997;130:679-80.
216. Agarwal AK, Saili A, Pandey KK, et al. Role of cimetidine in prevention and treatment of stress induced gastric bleeding in neonates. Indian Pediatr 1990;27:465-9.
217. Bush A, Busst CM, Knight WB, Shinebourne EA. Cardiovascular effects of tolazoline and ranitidine. Arch Dis Child 1987;62:241-6.
218. Kuint J, Lindex N, Reichman B. Hypoxemia associated with cimetidine therapy in a newborn infant. Am J Perinatol 1996;13:301-3.
219. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96.
220. Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984;19:916-22.
221. Nishina K, Mikawa K, Maekawa N, Tarnada M, Obara H. Omeprazole reduces preoperative gastric fluid acidity and volume in children. Can J Anaesth 1994;41:925-9.
222. Mikawa K, Nishina K, Maekawa N, Asano M, Obara H. Lansoprazole reduces preoperative gastric fluid acidity and volume in children. Can J Anaesth 1995;42:467-72.
223. De Giacomo C, Bawa P, Franceschi M, Luinetti O, Fiocca R. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32.
224. Karjoo M, Kane RE. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995;149:267-71.
225. Krischer J, Noblett H, Sandhu BK. The use of proton pump blocker for resistant reflux oesophagitis in children [abstr]. Gut 1992;33:S61.
226. Larson C, Cavuto NJ, Flockhart DA, Weinberg RB. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Dig Dis Sci 1996;41:475-9.
227. Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997;92:79-83.
228. Mohiuddin MA, Pursnani KG, Katzka DA, et al. Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules. Dig Dis Sci 1997;42:715-19.
229. Sharma VK, Heinzelmann EJ, Steinberg EN, Vasudeva R, Howden CW. Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered by a gastrostomy. Am J Gastroenterol 1997;92:848-51.
230. Woods DJ, McClintock AD. Omeprazole administration [letter]. Ann Pharmacother 1993;27:651.
231. Phillips JO, Metzler MH, Palmieri TL, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-1800.
232. Quercia RA, Fan C, Chow MSS. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm 1997;54:1833-6.
233. Nelis GF. Safety profile of omeprazole. Adverse events with short-term treatment. Digestion 1989; 44:68-76.
234. Melville C, Shah A, Matthew D, Milla P. Electrolyte disturbances with omeprazole therapy. Eur J Pediatr 1994;153:49-51.
235. De Giacomo C, Fiocca R, Villani L, et al. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinoginemia I in an infant. J Pediatr 1990;117:989-93.
236. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-9.
237. McCarthy DM. Drug therapy. Sucralfate. N Engl J Med 1991;325:1017-25.
238. Tryba M. Stress bleeding prophylaxis with sucralfate. Scand J Gastroenterol 1990;25:22-33.
239. Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG, Navarro-Merino M. Sucralfate in the treatment of reflux esophagitis in children. Scand J Gastroenterol 1989;24:43-7.
240. Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989;86:73-6.
241. Reddy AN. Sucralfate gastric bezoar [letter]. Am J Gastroenterol 1986;81:149-50.
242. Tryba M, Kurz-Muller, Donner B. Plasma aluminum concentrations in long-term mechanically ventilated patients receiving stress ulcer prophylaxis with sucralfate. Crit Care Med 1994;22:1769-73.
243. Moore JG, Coburn JW, Sanders MC, McSorley DJ, Sirgo MA. Effects of sucralfate and ranitidine on aluminum concentrations in elderly volunteers. Pharmacotherapy 1995;15:742-6.
244. Baines PB, Ratcliffe J, Petros A. Aluminum concentrations in critically ill children with renal impairment [letter]. Crit Care Med 1995;23:1931.
245. Siafakas C, Fox VL, Nurko S. Use of octreotide for the treatment of severe gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 1998;26:356-9.
246. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids of histamine type 2 blockers. The role of gastric colonization. N Engl J Med 1987;317:1376-82.
247. 2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991;19:942-9.
248. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996;275:308-14.
249. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998;338;791-7.